2m 2m 2m 2m 2m 2m 2m
Esperion Therap (ESPR)
NASDAQ
$3.16$0.00 (0.00%)
Price as of Jun 23, 2026 5:10 PM EDT- $814.3MMarket Cap
- 195.33%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Esperion Therap (ESPR)
$3.16$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 159.6M -51.98% | 332.3M +185.66% | 116.3M +54.14% | 75.5M -3.79% | |
Cost of Revenue | 129.2M N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 30.3M -90.87% | 332.3M +185.66% | 116.3M +54.14% | 75.5M -3.79% | |
Sales and Marketing Expense | 165.8M +1.66% | 163.1M +14.42% | 142.5M +30.66% | 109.1M -41.03% | |
Research and Development Expense | -47.9M +3.49% | -46.2M -46.30% | -86.1M -172.40% | 118.9M +12.22% | |
Depreciation and Amortization Expense | 105,000 +66.67% | 63,000 -61.59% | 164,000 -67.20% | 500,000 -18.30% | |
Total Operating Expenses | 342.9M +23.37% | 277.9M +2.21% | 271.9M +6.64% | 255.0M -16.45% | |
Operating Profit | 60.3M +10.79% | 54.4M +134.97% | -155.6M -13.34% | -179.5M -20.83% | |
Interest Income | 3.5M -53.95% | 7.6M +72.73% | 4.4M +83.33% | 2.4M +2,300.00% | |
Interest Expense | -18.9M +2,262.50% | -800,000 -98.64% | -59.0M +3.81% | -56.8M +22.56% | |
Interest Income and Expense and Net | -15.4M -326.47% | 6.8M +112.46% | -54.6M -196.07% | 56.8M +22.56% | |
Total Nonoperating Income and Expense | 3.5M -56.49% | 8.0M +51.62% | 5.3M +99.51% | 2.7M -33.28% | |
Income before Taxes | -20.8M -138.31% | 54.4M +134.97% | -155.6M -13.34% | -179.5M -20.83% | |
Income Taxes | 1.8M N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | 0 N/A | 0 +100.00% | -100,000 0.00% | -100,000 0.00% | |
Net Income | -22.7M -56.17% | -51.7M -75.27% | -209.2M -10.45% | -233.7M -13.17% | |
Net Income from Continuing Operations Applicable to Common | -20.8M -59.72% | -51.7M -75.27% | -209.2M -10.45% | -233.7M -13.17% | |
Basic EPS and Net Income | -0.11 -60.71% | -0.28 -86.21% | -2.03 -42.33% | -3.52 -62.19% | |
Diluted EPS and Net Income | -0.11 -60.71% | -0.28 -86.21% | -2.03 -42.33% | -3.52 -62.19% | |
Basic Weighted Average Shares | 207.9M +11.05% | 187.2M +81.54% | 103.1M +55.26% | 66.4M +129.76% | |
Diluted Weighted Average Shares | 207.9M +11.05% | 187.2M +81.54% | 103.1M +55.26% | 66.4M +129.76% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 167.9M +15.95% | 144.8M +76.01% | 82.2M -34.08% | 124.8M -40.27% | |
Short-Term Investments | N/A N/A | N/A N/A | 0 -100.00% | 42.1M -16.56% | |
Cash and Cash Equivalents and Short-Term Investments | 167.9M +15.95% | 144.8M +76.01% | 82.2M -50.71% | 166.9M -35.66% | |
Total Current Assets | 462.6M +36.86% | 338.0M +68.10% | 201.1M -18.49% | 246.7M -25.01% | |
Accumulated Depreciation | 2.2M +5.06% | 2.1M +3.08% | 2.0M -21.13% | 2.6M +24.38% | |
Property and Plant and Equipment and Net | 338,000 +33.07% | 254,000 N/A | 0 -100.00% | 164,000 -75.30% | |
Total Long-Term Assets | 338,000 +33.07% | 254,000 N/A | 0 -100.00% | 164,000 -75.30% | |
Total Assets | 465.9M +35.50% | 343.8M +67.07% | 205.8M -17.00% | 247.9M -35.02% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 54.6M N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 300.8M +22.16% | 246.2M +57.62% | 156.2M +69.24% | 92.3M +25.84% | |
Total Long-Term Debt | 249.5M +4.95% | 237.7M -9.13% | 261.6M +0.65% | 259.9M +0.63% | |
Total Long-Term Liabilities | 8.7M +240.04% | 2.6M -14.90% | 3.0M +354.14% | 665,000 N/A | |
Total Liabilities | 767.9M +4.82% | 732.5M +10.86% | 660.8M +15.58% | 571.7M -1.18% | |
Retained Earnings | -1.6B +1.42% | -1.6B +3.34% | -1.5B +15.62% | -1.3B +21.12% | |
Total Stockholders Equity | -302.0M -22.32% | -388.7M -14.57% | -455.0M +40.53% | -323.8M +64.40% | |
Total Shares Outstanding | 247.2M +24.95% | 197.8M +64.59% | 120.2M +57.00% | 76.6M +21.77% | |
Cash Flow | |||||
Cash from Operating Activities | -13.1M -44.65% | -23.7M -82.54% | -135.5M -22.50% | -174.8M -33.73% | |
Capital Expenditures | 0 -100.00% | 317,000 N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | 0 +100.00% | -317,000 -100.75% | 42.5M +424.43% | 8.1M +116.05% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 36.2M -58.16% | 86.5M +71.39% | 50.5M +54.76% | 32.6M -87.84% | |
Financials Ratio | |||||
Gross Margin | 19.02% N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | 37.77% +130.73% | 16.37% +112.24% | -133.72% -43.77% | -237.83% -17.71% | |
Return on Assets | -5.60% -70.25% | -18.83% -79.58% | -92.23% +24.25% | -74.23% +1.35% | |
Return on Equity | 6.57% -46.45% | 12.27% -77.17% | 53.74% -40.12% | 89.74% -51.13% | |
Revenue Growth | -51.98% -128.00% | 185.66% +242.94% | 54.14% +1,528.95% | -3.79% -94.22% | |
Current Ratio | 1.54 +12.02% | 1.37 +6.66% | 1.29 -51.84% | 2.67 -40.41% | |
Cash Ratio | 0.56 -5.09% | 0.59 +11.66% | 0.53 -61.05% | 1.35 -52.54% | |
Debt-to-Equity Ratio | -0.83 +9.88% | -0.75 N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.54 -37.01% | 0.85 N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow